Regarding the dual activity of TGF-β in cancer, it was reported that during chronic inflammation in HCV patients, the tumor-suppressor activity of TGF-β shifts into fibrogenic and thus leads to the risk of HCC (30, 31). Here, TGFB1 is linked to hepatocellular carcinoma.